Acorda Therapeutics (NASDAQ:ACOR) : During the past 4 weeks, traders have been relatively bearish on Acorda Therapeutics (NASDAQ:ACOR), hence the stock is down -4.71% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.43% relative to the S&P 500. The stock has risen by 0.85% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.18% in the past 4 weeks.
The company shares have dropped -24.27% from its 1 Year high price. On Dec 31, 2015, the shares registered one year high at $43.63 and the one year low was seen on May 20, 2016. The 50-Day Moving Average price is $26.60 and the 200 Day Moving Average price is recorded at $31.20.
The stock has recorded a 20-day Moving Average of 1.78% and the 50-Day Moving Average is 1.42%.
Acorda Therapeutics (NASDAQ:ACOR): stock turned positive on Friday. Though the stock opened at $25.66, the bulls momentum made the stock top out at $26.3 level for the day. The stock recorded a low of $25.54 and closed the trading day at $26.21, in the green by 2.18%. The total traded volume for the day was 610,635. The stock had closed at $25.65 in the previous days trading.
In an insider trading activity,The officer (Chief of Business Operations) of Acorda Therapeutics Inc, Lawrence David sold 500 shares at $25.09 on June 22, 2016. The Insider selling transaction had a total value worth of $12,545. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinsons disease, epilepsy, heart failure, MS, and spinal cord injury.